Keri Barr
Psychiatric/Mental Health · Bay Minette, ALNPI 1215300736
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,745 of the $34,587 with a category attached, or 74.4%. Otsuka America Pharmaceutical, Inc. accounts for 87.7% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2024 at $17,438 and has fallen 69.9% since, to $5,249 in 2025. Among psychiatric/mental health clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 331 payments — averaging $104.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$30K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$521
- Teva Pharmaceuticals USA, Inc.$512
- Neurocrine Biosciences, Inc.$498
- Johnson & Johnson$410
- plus $1K from 9 others
What the payments were for
- Speaking & faculty fees$25,74574%
- Travel & lodging$2,6798%
- Food & beverage$6,16418%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 118 | $30,328 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 53 | $1,103 |
| Alkermes, Inc. | 12 | $521 |
| Teva Pharmaceuticals USA, Inc. | 25 | $512 |
| Neurocrine Biosciences, Inc. | 21 | $498 |
| Johnson & Johnson | 24 | $410 |
| AbbVie | 32 | $370 |
| Lundbeck LLC | 14 | $275 |
| Corium, LLC | 7 | $226 |
| Sunovion Pharmaceuticals Inc. | 15 | $133 |
| Indivior Inc. | 3 | $59 |
| Axsome Therapeutics, Inc. | 2 | $50 |
| Lilly USA, LLC | 2 | $46 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$28,572
- ABILIFY ASIMTUFII$27,928
- LYBALVI$976
- CAPLYTA$123
How this compares
$34,587 in reported general payments places this provider in the 95th percentile of 378 psychiatric/mental health providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 14 | $471 |
| Olanzapine | 11 | $270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCOlanzapine | $46 | $27011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 378 psychiatric/mental health providers in Alabama.
Other psychiatric/mental health in Bay Minette
- Laura GrahamMontgomery$80K
- Yuliya SpencerBirmingham$65K
- John HayesMobile$30K
- Logan ThrasherHoover$22K
- Anthony PhillipsHelena$15K
- Ian KinzerHuntsville$15K
- Latisha AliHoover$15K
- Taylor BarrettGadsden$15K
- Angela GarrardGadsden$14K
- Hunter HutchisonMontgomery$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.